Cjc-1295-ipamorelin
GHRH Analog + Selective GHRP · 5mg/5mg Pre-Mixed Blend · Research Use Only
CJC-1295 + Ipamorelin is the most studied GH optimization stack in research peptide science, combining two compounds that work through entirely different receptor pathways to produce a synergistic, amplified growth hormone pulse. CJC-1295 (Modified GRF 1-29) is a GHRH analog that binds pituitary GHRH receptors. Ipamorelin is a selective ghrelin receptor (GHSR) agonist that provides a sharp, immediate GH release pulse without affecting cortisol or prolactin. Together they produce 3-8x baseline GH elevation — far exceeding either compound alone.
How it works: CJC-1295 mimics endogenous GHRH, binding to GHRH receptors on anterior pituitary somatotrophs with a ~30-minute half-life that produces pulsatile GH release mirroring the body's natural nighttime rhythm. Ipamorelin activates GHS-R1a via phospholipase C → IP3/DAG → calcium ion mobilization → GH vesicle exocytosis. Critically, ipamorelin's selectivity means it does not stimulate cortisol, prolactin, or ACTH — side effects common with older GHRPs. The combination hits two independent triggers simultaneously producing a synergistic GH pulse that preserves physiological pulsatility and IGF-1 feedback inhibition.
Research highlights:
- PubMed CJC-1295 (2006): Sustained, dose-dependent increases in GH and IGF-I in healthy adults
- Combination produces 3-8x baseline GH elevation vs either compound alone
- Ipamorelin selectivity confirmed: no cortisol or prolactin stimulation vs GHRP-6
- Pulsatile dosing preserves somatostatin feedback preventing receptor downregulation
Contents: CJC-1295 (no DAC) 5mg + Ipamorelin 5mg — pre-mixed, single vial
Form: Lyophilized powder
Purity: ≥98% (HPLC verified, both compounds)
Storage: -20°C, away from light and moisture
⚠ RESEARCH USE ONLY. This product is intended for laboratory and in vitro research purposes only. Not for human or animal consumption. Must be 21+ to purchase. These statements have not been evaluated by the FDA.